CTS DIVISION HAS BEEN SELECTED FOR A DIVISION ACHIEVEMENT AWARD
The Clinical Translational Division was recognized with an Achievement Award for “support of AACC’s first virtual meeting, Personalized Diagnostics Today, held in October 2014.” This virtual meeting demonstrated the laboratory’s critical role in the use of tandem mass spectrometry, genotyping, sequencing technologies, and high-resolution analysis to provide clinicians with personalized information for improved patient care. This was a joint meeting with the Molecular Pathology, Personalized Medicine, and Proteomics & metabolomics Divisions. On March 4, 2015 the CTS Division received a letter of congratulations from the President of the AACC, David Koch.

JOHN MILLS, PHD WINS THE BEST ABSTRACT AWARD OF THE CTS DIVISION

Abstract Title:
A-249, Combining Nanobody Immunoenrichment and MALDI-TOF Mass Spectrometry to Detect and Isotype Monoclonal Immunoglobulins

John Mills received a PhD in biochemistry from McGill University in Montreal, Quebec and currently completing his second year of the clinical chemistry post-doctoral fellowship at the Mayo Clinic in Rochester, MN. Dr. Mills has research interests in the clinical application of mass spectrometry to detect and quantitate monoclonal immunoglobulins.

CTS DIVISION EVENTS AT THE UPCOMING AACC 2015 ANNUAL MEETING
Divisions Networking and Awards Meeting – Sun., July 26th, 1-2:30 pm, Hyatt Regency Atlanta
AACC Pediatric and Maternal - Fetal, Clinical Translational Sciences, Industry and Informatics Divisions Joint Mixer – Sun., July 26th, 7:30-9 pm, Hyatt Regency Atlanta, Embassy C/D
CTS Division “Poster Walk” – Tues., July 28th, 12:30-1:30 pm

Additionally the following education sessions have been developed in cooperation with the Clinical Translational Science Division:
Is LC-MS/MS Right for Your Clinical Laboratories? What You Need to Know About the Technology and Finance Before Bringing It to Your Lab - Morning Short Course: #191002. Sun., July 26th, 10:30 am- Noon.
Recently Approved Biomarkers of Acute Kidney Injury (AKI) – Afternoon Short Course: #72214. Mon., July 27th, 2:30 – 5 pm.
Laboratory Medicine’s Role in Reducing Health Disparities – Afternoon Short Course: #73218. Tues., July 28th, 2:30 – 5 pm.
Targeted Mass Spectrometry as an Enabling Technology in the Clinical Laboratory – Afternoon Symposia: #35203. Thurs., July 30th, 11:30 am – 2 pm.
Dr. Zhu is a tenured Associate Professor and Medical Director of Clinical Chemistry and Toxicology, Director of Postdoctoral Clinical Chemistry Fellowship Program at the Medical University of South Carolina. He is board certified by the American Board of Clinical Chemistry (ABCC) in Clinical Chemistry, Toxicological Chemistry, and Molecular Diagnostics and a Fellow of the National Academy of Clinical Biochemistry (NACB). Yusheng had worked in clinical laboratories in China for over ten years before he moved to the United States. He completed postdoctoral fellowship in biochemistry and molecular biology at the University of Georgia and clinical chemistry and pharmacogenetics at the University of Louisville. Yusheng joined the American Association for Clinical Chemistry (AACC) in 2003 and served as the Chair of AACC Ohio Valley Section Awards Committee (2006) and Alternate Delegate of AACC Southeast Section (2007-2009). He served as the President of the North American Chinese Clinical Chemists Association (2012). Currently, he is the President of the Commission on Accreditation in Clinical Chemistry (ComACC), Chair of Clinical Translational Science Division and Chair of Southeast Section, Secretary of Proteomics & Metabolomics Division and Treasurer of Mass Spectrometry & Separation Science Division of AACC.

MESSAGE FROM THE CHAIR

It is my great pleasure and honor to serve as the Chair of the AACC Clinical Translational Science (CTS) Division and I am proud to be a member of this relatively new, but excellent Division. Under the leadership of the former Board of the Division, we have made significant progress. This year, AACC selected the Clinical Translational Science Division for “Achievement Award” for support of AACC’s first virtual meeting, Personalized Diagnostics Today, held in October 2014. The Division will be honored at the Divisions Management Group meeting. Congratulations!

- At the upcoming AACC Annual Meeting in Atlanta, Georgia, July 26-30, 2015, the Division will organize several educational and social events. I invite all of you to attend the following activities.
- The CTS Division along with the Pediatric and Maternal-Fetal Division, Industry, and Informatics Divisions will hold a Joint Mixer. This is a great opportunity for you to network with other members. During the event, the Division will present the CTS Division Best Abstract Award.
- At the Division’s traditional free “Lunch & Learn” session. Three experts will talk about biobanking, ovarian cancer biomarkers, and microfluidic flow cell. You will learn the advances in the area of clinical and translational science.
- Additionally, we will organize the CTS Division “Poster Walk”. You will have a chance to meet with many scientists conducting clinical and translational research and to exchange ideas with them.

I hope all Division members will be able to attend these exciting events at the upcoming AACC Annual Meeting and look forward to meeting you in Atlanta, Georgia.

Sincerely,

Yusheng Zhu, PhD, DABCC, FABC
Chair, AACC Clinical Translational Science Division
Sihe Wang, PhD is Section Head and Medical Director of Clinical Biochemistry and Director of Clinical Biochemistry Fellowship Training Program at Cleveland Clinic. He chairs clinical chemistry integration and standardization effort for the Cleveland Clinic Health System which includes one Florida hospital, eight community hospitals and eighteen family health centers in Northeast Ohio. Additionally, he is a Clinical Chemistry Professor, Cleveland State University. His expertise includes general clinical chemistry and clinical application of mass spectrometry. Sihe is a diplomate of the American Board of Clinical Chemistry since 2005 and a fellow of the National Academy of Clinical Biochemistry since 2006. Sihe is a member of the American Association for Clinical Chemistry (AACC) since 2000. He served as chair of AACC Northeast Ohio Section in 2008 and 2009 and the president of North American Chinese Clinical Chemistry Association (NACCCA) 2008-2009. Currently he serves as historian for NACCCA, treasurer for AACC Pediatric and Maternal Fetal division, secretary for AACC Clinical Translational Sciences division, delegate for AACC Northeast Ohio section, president-elect for the Commission on Accreditation in Clinical Chemistry (ComACC), and member of AACC's Strategies Online Editorial Advisory Board.

Dr. Ricchiuti is the founder and past-president of the Clinical Translational Science (CTS) Division of the AACC. In April 2015, Dr. Ricchiuti joined Laboratory Corporation of America (LabCorp) in Dublin, Ohio as Laboratory Director/Medical Director and Technical Director. He is currently Chair of the AACC Ohio Valley Section. Previously, from 2012-2015, Dr. Ricchiuti was the Director of Clinical Chemistry and Toxicology at the University of Cincinnati Medical Center (UCMC), and Associate Professor at the University of Cincinnati, Department of Pathology and Laboratory Medicine at the College of Medicine, in Cincinnati, Ohio. Prior to working at UCMC, Dr. Ricchiuti was the Senior Director of Clinical Biomarkers at Medpace Reference Laboratories (MRL), in Cincinnati, OH. At MRL, Dr. Ricchiuti was the clinical chemistry and scientific liaison with sponsors for assay development at a global level including the USA, China, Europe and India. For 12 years, Dr. Ricchiuti was head of Clinical Research and Endocrinology Division Clinical Laboratories at Brigham and Women's Hospital (BWH) and Harvard Medical School (HMS), Boston MA. From 2008-2011, he was the Director of Harvard Catalyst Central Laboratories, formerly National Institute of Health-Clinical Research and Translational Medicine Center. Dr. Ricchiuti was very involved in AACC local section and was Chair of the Northeast Division of the AACC during his time in Boston. Dr. Ricchiuti received his Ph.D. at University Louis Pasteur, Strasbourg, France followed by a one-year post-doctoral research fellowship and two-year Clinical Chemistry fellowship training under Dr. Fred Apple, Hennepin County Medical Center, Minneapolis, MN.
Dr. Peck Palmer is an Assistant Professor at the University of Pittsburgh School of Medicine with appointments in the Departments of Pathology, Critical Care Medicine and Clinical and Translational Sciences. She is the Director of the Automated Testing Laboratories at the University of Pittsburgh Medical Center Presbyterian and Shadyside Hospitals and Children’s Hospital of Pittsburgh. She earned a B.S. in Biology from Columbia College, Columbia, SC, a Ph.D. in Physiology from the Medical University of South Carolina in Charleston, SC and completed a postdoctoral fellowship in clinical chemistry at Washington University School of Medicine in Saint Louis, MO. She has received numerous awards for her research which includes: Best Poster Winner-Animal Clinical Chemistry Division, Paul E. Strandjord Young Investigator Award with Distinction from ACLPS, the Society of Young Clinical Laboratorians Travel Grant, and 1st Place Poster Winner-Pediatric Maternal Fetal Division. Currently, her research program is funded by a NIH KL2 grant that is focused on understanding the role that single-nucleotide polymorphisms in zinc proteins play in mediating racial differences in the susceptibility to community-acquired pneumonia and risk of severe sepsis.

Judith Finlay has a Ph.D. in biochemistry from the University of Wisconsin-Madison and was a postdoctoral scholar at the University of California Los Angeles. She has extensive research and development experience at a variety of internationally known clinical diagnostic and biotechnology companies such as Hybritech Incorporated, Beckman Coulter, Invitrogen and Gen-Probe. She has authored numerous peer-reviewed publications on the use of biomarkers for cancer diagnostics. She is currently Director of Scientific Affairs at The Binding Site, Inc. in San Diego, California. At The Binding Site, she educates physicians, clinical laboratory personnel and patients on the use of the company’s serum free immunoglobulin light chain (Freelite™) and Heavy-chain, light chain pair (Hevylite™) immunoassays for management of multiple myeloma. She also educates clinical laboratory personnel on the use of immunoassays for the assessment of patients with primary immunodeficiency.
15-A-6-AACC
B-064: CLIA-PCR: a High-Throughput PCR Technology for Molecular Screening, with an Application in Malaria Surveillance for Elimination

15-A-233-AACC
B-189: MELPA: a Novel Technology for High-throughput, Multiplex Genotyping Directly from Dried Blood Spot without DNA Extraction, with an Application in the Screening of Multiple G6PD Gene Variants at Risk for Drug-induced Hemolysis

15-A-254-AACC
A-341: Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes

15-A-498-AACC
B-081: Association of HLA-DP/DQ Polymorphisms with transplant etiologies and liver function recovery in liver transplant recipients

15-A-573-AACC
A-067: Hair cortisol as a biomarker of the HPA axis in pregnant women with asthma

15-A-588-AACC
A-216: Alternatives to Oligoclonal Banding Electrophoresis in CSF: Method Comparison with Quantitative Free Light Chains and Accurate Molecular Mass Measurement of Immunoglobulins

15-A-633-AACC
B-267: Development and Validation of a Paper-based analytical disc assay for rapid and multiplex blood typing

15-A-672-AACC
B-219: CLSI-based Transference of CALIPER Pediatric Reference Intervals to the Roche Cobas 6000 and the Roche Modular System

15-A-686-AACC
B-283: A Comprehensive Database of Pediatric and Adult Reference Intervals for Biochemical Markers based on the Canadian Health Measures Survey (CHMS)

15-A-957-AACC
A-248: High Resolution Accurate-mass Mass Spectrometry (HRAMS) Offers Superior Accuracy For Quantitation of Steroids and Proteins

15-A-1033-AACC
A-286: Development of a serum based exosomal biomarker signature to distinguish indolent and aggressive prostate cancer. Circulating BCMA Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients

15-A-1065-AACC
15-A-1065-AACC
A-249: Combining Nanobody Immunoenrichment and MALDI-TOF Mass Spectrometry to Detect and Isotype Monoclonal Immunoglobulins

15-A-1119-AACC
A-260: Vedolizumab Quantitation in Serum using SRM And microLC-ESI-Q-TOF Mass Spectrometry

15-A-1135-AACC
A-372: The Role of Circulating Angiogenesis-Associated Factors in Early-Stage Non-Small Cell Lung Cancer: Implications for Mechanistic Insights and Improved Methods for Prognostication

Sponsors of the American Association for Clinical Chemistry, Clinical Translational Science Division, Lunch and Learn Meeting Mon., July 27th, Noon- 2:30 pm, Hyatt Regency Atlanta, Hanover  D/E.

Platinum Sponsor: Roche Diagnostics

Silver Sponsor: DSI – The Biobanking Automation Company

Bronze Sponsors: Fujirebio Diagnostics, Inc

Taiwan Semiconductor Manufacturing Company

SONY DADC Bioscience

Newsletter Edited by: Peggy Emmett, MA, MT(ASCP)